RxDoctor Payments Data

Nan Jiang, MD

Family Medicine · Houston, TXNPI 1407883259

Payments from drug & device makers

$403,051in general payments, 2019–2025

Across 547 payments — averaging $736.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$218K
  • Genentech, Inc.$115K
  • Phathom Pharmaceuticals, Inc.$33K
  • Astrazeneca UK Limited$17K
  • Amarin Pharma, Inc.$5K
  • Astrazeneca AB$5K
  • plus $10K from 37 others

What the payments were for

  • Food & beverage$8,698100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403,051 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$123,261
Medicare patients
264
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$82,172
FarxigaDapagliflozin Propanediol62$77,262
JardianceEmpagliflozin63$68,714
TrulicityDulaglutide23$38,121
EliquisApixaban26$36,044
VascepaIcosapent Ethyl34$29,152
JanuviaSitagliptin Phosphate21$28,352
JanumetSitagliptin Phos/Metformin Hcl15$16,384
Tresiba Flextouch U-200Insulin Degludec11$12,493
Atorvastatin Calcium477$4,669
Losartan Potassium252$2,872
Olmesartan Medoxomil43$2,358
Rosuvastatin Calcium111$2,053
Levothyroxine Sodium220$2,048
SynthroidLevothyroxine Sodium25$2,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,785$82,17264 claims
AstraZenecaFarxiga$1,734$77,26262 claims
Boehringer IngelheimJardiance$319$68,71463 claims
MerckJanuvia, Janumet$875$44,73636 claims
Lilly USA, LLCTrulicity$780$38,12123 claims
PfizerEliquis$249$36,04426 claims
AbbVieSynthroid$274$2,04125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →